Shasqi


Shasqi is a biotech company focused on making cancer drugs more effective through innovative click chemistry technology. Their proprietary CAPAC platform enables targeted activation of therapeutics at tumor sites, reducing systemic toxicity and expanding treatment possibilities. They are advancing a diverse pipeline of tumor-targeting agents and payloads, validated in clinical studies, with a mission to improve cancer treatment outcomes.

Industries

Biotechnology
Emergency Medicine
Health Care
Medical
Biotechnology Research

Nr. of Employees

small (1-50)

Shasqi

San Francisco, California, United States


Products

Intratumoral biopolymer activator paired with systemically administered protodrugs

A therapeutic approach combining a locally delivered biopolymer activator that presents click-reactive groups at the tumor and a systemically dosed chemically attenuated protodrug that is activated on-site via in vivo click chemistry.

Systemically delivered protodrug payloads for multiple modalities

Protodrug constructs designed for chemotherapeutics, highly toxic cytotoxins, immune agonists and radiotherapeutic payloads that remain inactive in circulation until clicked at the tumor-localized activator.

CAPAC

Click Activated Protodrugs Against Cancer (CAPAC) is a pre-targeting platform that uses click chemistry to reunite a binder and payload at the tumor, avoiding off-target toxicities.

SQ3370

A clinical asset within the CAPAC platform that activates a doxorubicin protodrug at the tumor with an intratumorally injected biopolymer.


Services

Collaborative research and development partnerships to apply in vivo click chemistry pre-targeting to external antigen targets and payloads, including co-development of activators and protodrugs.

Preclinical program execution including protodrug synthesis, activator design, animal efficacy and tolerability studies, PK/BD analysis, and immune response assessment to support clinical translation.

Expertise Areas

  • Pre-targeting oncology therapeutics
  • In vivo bioorthogonal (click) chemistry
  • Protodrug (prodrug) design and medicinal chemistry
  • Tumor-targeting activator engineering (antibodies, fragments, peptides, VHH)
  • Show More (5)

Key Technologies

  • In vivo click chemistry (bioorthogonal reactions)
  • Chemical protodrug design and attenuation
  • Injectable biopolymer activators (hyaluronate derivatives)
  • Antibody- and peptide-based targeting agents
  • Show More (4)

News & Updates

Shasqi published a landmark study in Clinical Cancer Research detailing the development and first-in-human trial of SQ3370, a click chemistry-based cancer therapeutic that allows higher doses of doxorubicin to be delivered directly to tumors with reduced toxicity.

A significant publication by Shasqi in Clinical Cancer Research highlights the first-in-human use of click chemistry for targeted cancer therapy, demonstrating the platform's potential to revolutionize oncology treatments.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.